BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

BioPharma Clinical Trials

Nuvation Bio Launches Expanded Access Program in the U.S. for Taletrectinib in ROS1+ NSCLC

Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, announced it has initiated ...

February 04, 2025 | News

Bristol Myers Squibb’s Breyanzi Recommended for EU Approval After 97% Response Rate in Follicular Lymphoma

Recommendation based on the Phase 2 TRANSCEND FL study in which 97.1% of patients responded to Breyanzi, with 94.2% of patients achieving comple...

February 03, 2025 | News

China Approves Sarclisa as First Anti-CD38 Therapy for Newly Diagnosed Multiple Myeloma Patients

Sarclisa is the first anti-CD38 treatment approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant A...

January 31, 2025 | News

Kazia Therapeutics Launches Clinical Trial for Paxalisib-Immunotherapy Combination in Advanced Breast Cancer

Kazia Therapeutics Limited an oncology-focused drug development company, is pleased to announce the regulatory approval and launch of a clinical trial eval...

January 31, 2025 | News

Cognizant and Medidata Expand AI-Driven Partnership to Advance Clinical Trials

The organizations plan to support clients through expanded partnership and offer broader access to Medidata's AI-powered technologies to accelerate clinica...

January 31, 2025 | News

Clarity Pharmaceuticals Secures Second FDA Fast Track Designation for 64Cu-SAR-bisPSMA in Prostate Cancer Imaging

Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation product...

January 27, 2025 | News

Akeso Secures CDE Approval for IL-17 Monoclonal Antibody Gumokimab to Address Plaque Psoriasis

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the New Drug Application (NDA) of its internally-developed IL-17-targeting mon...

January 27, 2025 | News

Kelun-Biotech Secures NMPA Approval for Tagitanlimab in First-Line Treatment of Nasopharyngeal Cancer

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company received marketing authorization in China from Natio...

January 24, 2025 | News

Allurion Technologies to Initiate Clinical Study Combining Allurion Program with GLP-1 Therapy to Transform Obesity Care

Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced its ...

January 24, 2025 | News

GI Innovation and LaNova Medicines Join Forces for Breakthrough Pancreatic Cancer Combination Therapy

GI Innovation (KQ:358570) announced that it signed a Memorandum of Understanding (MOU) with LaNova Medicines (LaNova) for the development o...

January 23, 2025 | News

Lepu Biopharma Partners with ArriVent BioPharma for Global Development of MRG007, a Promising ADC for GI Cancers

Lepu Biopharma Co., Ltd (Stock Code: 02157.HK) announced that it has entered into an exclusive licensing agreement with ArriVent BioPharma, Inc.&...

January 23, 2025 | News

Ascletis Pharma Reports Promising Results for ASC30 Oral Tablet in Obesity Treatment

ASC30 oral tablet demonstrated dose-proportional pharmacokinetic (PK) properties and a long half-life (t1/2) up to 60 hours in the single ascending dose ...

January 22, 2025 | News

YolTech Therapeutics Launches Clinical Trial for YOLT-204 a First-in-Class Gene Editing Therapy for Beta-Thalassemia

YolTech Therapeutics, a clinical-stage gene editing company dedicated to delivering lifelong cures, announced the initiation of a clinical trial for Y...

January 21, 2025 | News

Medidata Leads the Way in Sustainable Clinical Trials with EU Taxonomy Certification

-Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, today announced that Medid...

January 17, 2025 | News

Stay Connected